Descripción de la empresa
Precision BioSciences, Inc. operates as a clinical stage gene editing company focused on developing in vivo gene editing therapies specifically designed for gene edits such as insertion, excision, and elimination within the United States. The firm leverages its proprietary ARCUS platform, which facilitates DNA genome insertion, removal, and repair, to advance its therapeutic pipeline. This entity functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, a domain characterized by high R&D expenditures and long development cycles prior to commercialization. The company's current scale is defined by a market capitalization of $154.79M and an annual revenue of $34.26M, supported by a workforce of 68 employees. These financial figures indicate that the company maintains a relatively small market presence compared to large-cap pharmaceutical peers, suggesting a pre-revenue or early commercialization phase where capital allocation is heavily directed toward research and development rather than shareholder returns or massive operational scaling.
Salud financiera
The company reported a trailing twelve-month revenue of $34.26M, yet it recorded a net income of -$46,609,000, revealing a significant gap between top-line generation and bottom-line profitability. This disparity highlights a cost structure dominated by high operational expenses, likely driven by clinical trial costs, research infrastructure, and personnel, which is typical for clinical-stage biotechnology firms. Additionally, the EBITDA stands at -$50,680,000, further confirming that current operations are not yet generating positive cash from core activities before financing costs. The free cash flow is reported at -$21,974,250, indicating a burn rate that necessitates ongoing access to capital markets or existing reserves to fund future milestones without diluting shareholders excessively. Despite the negative income metrics, the balance sheet holds $115.58M in cash against $28.81M in debt, creating a substantial net cash position that provides a buffer for operational continuity. The debt-to-equity ratio is calculated at 31.23, suggesting a leveraged capital structure relative to equity, though the high cash balance mitigates immediate solvency risks. The current ratio of 13.32 demonstrates an extremely strong short-term liquidity position, meaning the company possesses ample liquid assets to cover its short-term obligations many times over. Finally, the return on equity is -62.7% and the return on assets is -22.4%, metrics that reflect the reality that management is currently deploying capital to build value rather than returning it, resulting in negative returns until the first commercial sales occur.
Evaluación de valoración
Valuation multiples for Precision BioSciences present a mixed picture given the lack of consistent earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -1.84. The negative forward P/E implies that analysts or market participants expect earnings to remain negative or that the current pricing does not yet reflect a profitable earnings trajectory in the near term. The price-to-book ratio stands at 1.63, indicating that the market values the company at a 63% premium over its net asset book value, which often reflects the intrinsic value of its intellectual property and clinical pipeline. Alternative valuation metrics such as the price-to-sales ratio of 4.52 and an EV/EBITDA of -1.34 suggest that the market is pricing the stock based on revenue generation potential and asset backing rather than current profitability. The stock has traded between a 52-week high of $8.82 and a 52-week low of $3.53, placing the current valuation within a range that reflects significant volatility typical of small-cap biotech stocks. The beta of 1.09 indicates that the stock's price volatility moves in tandem with the broader market, showing slightly higher sensitivity to market swings than a standard market basket.
Growth & Income
Revenue growth for the trailing twelve months is exceptionally high at 5261.1%, a figure that typically results from the transition from negligible prior-year revenues to current commercial or licensing sales. Earnings growth is listed as N/A due to the absence of positive net income, meaning the expansion of profitability cannot be measured in traditional percentage terms until the company achieves breakeven. Unlike mature dividend-paying stocks, Precision BioSciences, Inc. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This zero payout ratio confirms that the company reinvests all available earnings and cash reserves into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is characterized by rapid top-line expansion without current profitability or dividend income, positioning the asset as a pure-play investment in future therapeutic potential rather than current cash flow generation.